LYMPHATIC FILARIASIS Community medicine.pptx

qdhyqdqqq9 76 views 67 slides Jul 19, 2024
Slide 1
Slide 1 of 67
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36
Slide 37
37
Slide 38
38
Slide 39
39
Slide 40
40
Slide 41
41
Slide 42
42
Slide 43
43
Slide 44
44
Slide 45
45
Slide 46
46
Slide 47
47
Slide 48
48
Slide 49
49
Slide 50
50
Slide 51
51
Slide 52
52
Slide 53
53
Slide 54
54
Slide 55
55
Slide 56
56
Slide 57
57
Slide 58
58
Slide 59
59
Slide 60
60
Slide 61
61
Slide 62
62
Slide 63
63
Slide 64
64
Slide 65
65
Slide 66
66
Slide 67
67

About This Presentation

filariasis


Slide Content

LYMPHATIC FILARIASIS

Contents Introduction Problem statement Epidemiological Triad Lifecycle Clinical Manifestations Investigations ELF IVC National Filaria Day & IEC Assessment parameters

Introduction Latin origin: Filaria – Fil (um) – Slender or thread like Lymphatic Filariasis is caused by infection with parasites classified as nematodes ( roundworms ) of the family Filarioidea.

Lymphatic Filariasis (LF) is one of the oldest and most debilitating neglected tropical diseases (NTDs). Caused by three species of parasitic worms: Wuchereria bancrofti (90%) Brugia malayi (~10%) B. timori Transmitted to humans by mosquitoes.

Problem Statement Over 882 million people in 44 countries worldwide remain threatened by lymphatic filariasis and require preventive chemotherapy As of 2018, 51 million people were infected – a 74% decline since the start of WHO’s Global Programme to Eliminate Lymphatic Filariasis in 2000. Of which 65% live in WHO-SEAR, 30% live in WHO-African region

EPIDEMIOLOGICAL TRIAD

1. Agent Adult worms lodge in the lymphatic vessels and disrupt the normal function of the lymphatic system. The worms can live for an average of 6–8 years and during their life time, produce millions of microfilariae (immature larvae) that circulate in the blood.

Agent Factors S.No Parasite Mosquito Disease 1. W.bancrofti Culex LF 2. B.malayi Mansonia LF 3. B.timori Anopheles/ Mansonia LF 4. O.volvulus Simulium flies River Blindness 5. L.loa Chrysops flies S/c swellings 6. M.perstans Culicoides Serous cavity 7. M. streptocerca Culicoides Serous cavity 8. M.ozzardi Culicoides Serous cavity

2. Host Man – Natural Host Age – All age Sex – Higher in men Migration – leading to extension of infection to non-endemic areas Immunity – may develop after long year of exposure (Basis of immunity-not known)

3. Environment Mosquitoes are infected with microfilariae by ingesting blood when biting an infected host. Major vectors of W. Bancrofti : Culex  mosquito in urban and semi-urban areas,  Rarely in Anopheles mainly found in rural areas, and  Also rarely in Aedes mainly in endemic islands in the Pacific Vector of B. Malayi : Mansonia (mostly) Anopheline (some areas)

Associated with Urbanization, Poverty, Industrialization, Illiteracy and Poor sanitation. Climate is an important factor which influences: The breeding of mosquito Longevity (Optimum temperature 20-30 C & Humidity 70%) The development of parasite in the vector Sanitation, Town planning, Sewage & Drainage.

Life cycle

Clinical Manifestations It is of 2 types: Lymphatic Filariasis (Presence of Adult worms) Occult Filariasis ( Immuno hyper responsiveness)

I. Lymphatic Filariasis 4 Clinical stages: Stage 1: Asymptomatic amicrofilariaemic stage Stage 2: Asymptomatic microfilariaemic stage Stage 3: Stage of Acute manifestation Stage 4: Stage of Obstructive (Chronic) lesions

A symptomatic a microfilariaemic stage Stage 1: In endemic areas, a proportion of population does not show microfilariae or clinical manifestation. Laboratory diagnostic techniques are not able to determine whether they are infected or free.

A symptomatic microfilariaemic stage Stage 2: Certain proportions are clinically asymptomatic (months and years) + circulating microfilariae present. Remain as an important source of infection . Night Blood Survey .

Stage of Acute manifestation Stage 3: Recurrent episodes of Acute inflammation in the lymph vessel/node of the limb & scrotum. Clinical manifestations are: Filarial fever (ADL-DLA) Adenolymphangitis-dermatotolymphangitis Lymphangitis Lymphadenitis Epididymo orchitis

Acute dermatolymphangioadenitis (ADLA) It's an inflammation of the skin, subcutaneous tissue, lymphatics, and lymph nodes in the affected area.  ADLA attacks are often associated with fever and chills, and usually occur in the limbs or scrotum, along with lymphedema

Stage of Obstructive ( Chronic ) lesions Stage 4: It is the permanent damage to the lymph vessels caused by the adult worms. Dilation of the lymph vessels occur due to recurrent inflammatory episodes ---> endothelial proliferation and granuloma formation around the parasite. It takes 10-15 years .

Pitting oedema ---> browny oedema ---> hardening of tissues ---> hyperpigmentation, keratosis , wart like lesions. Late stages- Non pitting edema Hydrocoele (40-60%). Elephantiasis of Legs , Scrotum, Arm, penis , Vulva, Breast and Chyluria.

Clinical stages of Lymphedema A total of 7 stages are present. Distinguished with presence or absence of: Oedema , Folds, Knobs, Mossy foot, Disability

Stage I Swelling reverses at night Skin folds - Absent Appearance of Skin – Smooth & Normal Stage II Swelling not reversible at night Skin folds - Absent Appearance of skin - Smooth, Normal

Stage III Swelling not reversible at night Skin folds - shallow Appearance of Skin – Smooth & Normal Stage IV Swelling not reversible at night Skin folds - shallow Appearance of Skin – Knobs & Nodules

Stage V Swelling not reversible at night Skin folds - deep Appearance of Skin – Smooth & Irregular Stage VI Swelling not reversible at night Skin folds – shallow or deep or irregular Appearance of Skin – Wart like like lesions on toe and foot

Stage VII Swelling not reversible at night Skin folds – shallow or deep or irregular Appearance of Skin – Irregular Needs help for daily activities - Walking, bathing, using bathrooms - Dependent on family or health care systems

Brugian filariasis : Rarely involves genitalia Differential diagnosis: Obstructions following Tumors Tuberculosis Surgery Irradiation Ethiopia: Endemic leg Elephantiasis is caused by silica deposition in iliac lymph nodes

II. Occult Filariasis Classical clinical manifestation will be absent . Hyper-responsiveness to filarial antigens derived from mf. Males > Females

Patients present with Paroxysmal cough Wheezing Low grade fever Scanty sputum with occasional haemoptysis Adenopathy Eosinophilia (high-grade) X-ray shows diffused nodular mottling and interstitial thickening.

Investigations Epidemiological screening: 20 cmm finger prick blood, dried flat on a slide, stained and examined for mf Xenomonitoring : (L3 larvae) Vector mosquitoes are collected and examined for the presence of parasite (dissection) or parasite material (Polymerase Chain Reaction) using molecular technique. Presence of infective stage larva of LF is considered as an indication of current risk of transmission and presence of microfilaria carriers in the community as well.

Management Treating the infection Treatment and prevention of Acute ADL A attacks Treatment and prevention of Lymphoedema

Chemotherapy Drugs effective against filariasis: Diethyl Car bamazine citrate (DEC) Ivermectin Albendazole

DEC Effective Microfilaricidal Effective against adult worms in 50% of patients Dose: 6mg/kg for 12 days Recent dosage: 6mg/kg single dose Adverse reactions are mostly due to the rapid destruction of mf which is characterized by fever, nausea, myalgia , sore throat, cough, headache. No effect : Treating ADLA

Ivermectin Effective microfilaricidal Dose: 150-200 µg/kg No action on adult worms Drug of choice in Co-endemic areas of Onchocerciasis with LF Adverse reactions are lesser but similar to that of DEC Mf reappears faster than DEC

Albendazole It is antihelmenthic and kills adult worms No action on microfilariae Dose: 400mg BD for 14 days With combination of DEC & Ivermectin , it enhances the action of the drugs. It induces severe adverse reactions in hydrocele cases due to the death of adult worms.

DEC fortified salt DEC medicated salt is also a form of Mass treatment using low dose of drug over a long period of time (1-2 gm /Kg of Salt).

Lymphedema Management Early detection of lymphoedema Skin care Washing and drying Preventing and treating entry lesions Providing lymph drainage by elevation and exercises Wearing proper foot-wear

Management of uncomplicated ADLA Analgesic: Tab Paracetamol 1g, TDS Antibiotic: Tab Amoxicillin 500 mg, TDS * 8days Clean the limb with antiseptic Check for wounds, cuts, abscess, interdigital infection and give appropriate antibiotic or antifungal No antifilarial medicine Follow-up after 2 days

Entry lesions & Ulcers

Management of severe ADLA Secondary to infections Inj Benzyl Penicillin i.v 3 million units 3 times a day or Inj Procaine Penicillin i.m 5 million units 2 times a day till fever subsides. Followed by, oral phenoxymethylpenicillin 750 mg – 1 g given 3 times a day. If penicillin allergy, give Inj Erythromycin iv 1 g 3 times a day until fever subsides followed by oral Erythromycin 1 g 3 times a day. Analgesic/ Antipyretic No anti-filarial medicine

Surgical Management Hydrocele : Excision Scrotal Flip: Surgical removal of Skin & Tissue, preserving penis and testicles. Lymphoedema (Elephantiasis): Excision of redundant tissue, Excision of subcutaneous and fatty tissues Postural drainage and physiotherapy

Control of LF NFCP launched in 1955 Strategies: Vector control Detection and treatment of filarial cases Delimitation of endemic areas. Control units, Night clinics and Survey teams

Global Programme to ELF

NHP 2002 Goal: To eliminate lymphatic filariasis (ELF) from India by the year 2015 Objectives: ( i ) To reduce and eliminate transmission of LF by Mass Drug Administration of anti-filarial drugs (DEC or DEC + Albendazole ) (ii) To reduce and prevent morbidity in affected persons

ELF LF ceases to be a public health problem, when The number of microfilaria carriers is less than one per cent and The children born after initiation of ELF are free from circulating antigenaemia . Absence of antigenaemia among children is considered as evidence for absence of transmission and new infection.

STRATEGY: Transmission control (prevent the occurrence of new infection and disease) by administration of annual single dose of anti-filarial drug i.e. DEC and/or coadministration of DEC+ Albendazole . Disability Prevention and Management – for those individuals who already have the disease Home based: Limb hygiene for lymphoedema Hospital based: Surgical Correction

Mass Drug Administration To approach every individual in the target community and administer annual single dose of anti-filarial drugs (DEC or DEC + Albendazole ). This annual dose is to be repeated every year for a period of 5 years or more aiming at minimum 85 % actual drug compliance.

“supervised drug administration by door to door visit supplemented with drug administration at booths and groups” Over 85% coverage of the population for at least 5 years could effectively interrupt transmission.

Effect OF MDA

Integrated Vector Control Vector control involves Anti larval measures Anti adult measures Personal prophylaxis An integrated method using all the vector control measures alone will bring about sustained vector control

I. Anti larval measures: 1. Chemical control Mosquito larvicidal oil Pyrosene oil Organo phosphorous compounds such as Temephos , Fenthion , 2. Removal of pistia plants 3. Minor environmental measures

II. Anti adult measures: Anti adult measures as indoor residual spray using DDT, HCH and Dieldrin. Pyrethrum as a space spray is also followed. III. Personal Prophylaxis: Reduction of man mosquito contact by using mosquito nets, screening of houses, etc.

National Filaria Day November 11 Mass Drug Administration is to be observed on a single day as National Filaria Day. Besides free drug distribution, there are additional inputs in the form of IEC, expenses, training, monitoring and evaluation of the project.

IEC

Assessment of Filaria control programmes FILARIAL INDICES Clinical Parameters Parasitological Parameters Entomological Parameters

1. Clinical Parameters Incidence of acute manifestations Adeno-lymphangitis Epididymo-orchitis , etc Prevalence of chronic manifestations Lymphedema Elephantiasis Hydrocele Chyluria , etc

2. Parasitological Parameters Microfilaria rate: Percentage of persons examined in the sample population showing Mf in their peripheral blood Filarial endemicity rate: Percentage of persons examined in the sample population showing Mf in the blood or disease manifestation or both

Microfilarial Density: It is the number of Mf per unit volume of blood in samples from individual persons ---> Intensity of infection Average Infestation Rate: It is the average number of Mf per positive slide ---> Prevalence of microfilaraemia

3. Entomological parameters Vector density per 10 man-hour catch Percentage of mosquitoes positive for all stages of development Percentage of mosquitoes positive of infective larvae L3 (Mosquito infection rate) Annual biting rate- assessment of transmission

THANK YOU...
Tags